HR and breast cancer: MONARCH PLUS is a randomized, double-blind, placebo-controlled, phase III study to compare anastrozole or letrozole plus abemaciclib or plus placebo and to compare fulvestrant plus abemaciclib or plus placebo in postmenopausal women with HR+/HER2− locoregionally recurrent or metastatic BC [47].